Literature DB >> 15283822

Buprenorphine blocks withdrawal in morphine-dependent rat pups.

Dawn C Stoller1, Forrest L Smith.   

Abstract

BACKGROUND: Infants placed on extracorporeal membrane oxygenation (ECMO) or mechanical ventilation often need continuous morphine infusions for pain relief and sedation. The resulting physical dependence requires an additional 2-3-week hospital stay to taper the morphine to avoid withdrawal. Buprenorphine effectively blocks abstinence in dependent adults, and in infants it could accelerate or eliminate the tapering schedule, thereby enabling earlier hospital dismissals.
METHODS: Morphine-dependent infant rats were used in this study to determine the effectiveness of buprenorphine in blocking abstinence. Postnatal day-14 (P14) rats were implanted with osmotic minipumps that delivered saline (1 microl x h(-1)) or morphine (2 mg x kg(-1) h(-1)) for 72 h. The minipumps were then removed to allow the rats to undergo spontaneous morphine withdrawal.
RESULTS: The withdrawal period lasted approximately 72 h out of a 96-h observation period. The following signs were significant during these hours: wet-dog shakes, 1-72 h; abdominal stretches, 1-72 h; forepaw tremors, 1-24 h; splayed hind-limbs, 1-72 h; ptosis, 4-72 h; and evoked vocalization, 4 and 8 h. A single 1 mg x kg(-1) buprenorphine dose significantly decreased wet-dog shakes from 1 to 72 h, abdominal stretches from 1 to 48 h, forepaw tremors and splayed hind-limbs 1-8 h, and ptosis and evoked vocalization at 4 and 8 h. Repeated administration of 1 mg x kg(-1) buprenorphine before pump removal and at 24, 48 and 72 h resulted in a greater magnitude of blockade of abstinence throughout the 96-h observation period.
CONCLUSIONS: Buprenorphine may prove to be a suitable drug for treating opioid withdrawal in human infants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15283822     DOI: 10.1111/j.1460-9592.2004.01264.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  5 in total

1.  Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats.

Authors:  Dawn C Stoller; Laura J Sim-Selley; Forrest L Smith
Journal:  Brain Res       Date:  2007-01-13       Impact factor: 3.252

Review 2.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

3.  Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.

Authors:  Norsyifa Harun; Illa Syafiqah Johari; Sharif Mahsufi Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2019-12-12       Impact factor: 4.530

4.  Opioid analgesia in mechanically ventilated children: results from the multicenter Measuring Opioid Tolerance Induced by Fentanyl study.

Authors:  Kanwaljeet J S Anand; Amy E Clark; Douglas F Willson; John Berger; Kathleen L Meert; Jerry J Zimmerman; Rick Harrison; Joseph A Carcillo; Christopher J L Newth; Stephanie Bisping; Richard Holubkov; J Michael Dean; Carol E Nicholson
Journal:  Pediatr Crit Care Med       Date:  2013-01       Impact factor: 3.624

5.  Comparative benefits of social housing and buprenorphine on wheel running depressed by morphine withdrawal in rats.

Authors:  Jonah D Stickney; Michael M Morgan
Journal:  Psychopharmacology (Berl)       Date:  2021-07-10       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.